Analysts are on the Bearish side about Celgene Corporation (NASDAQ:CELG) this week.

Celgene Corporation (NASDAQ:CELG) Logo
Investors sentiment increased to 0.76 in 2019 Q1. Its up 0.12, from 0.64 in 2018Q4. It increased, as 108 investors sold Celgene Corporation shares while 441 reduced holdings. 204 funds opened positions while 213 raised stakes. 482.72 million shares or 1.75% less from 491.33 million shares in 2018Q4 were reported.
Empyrean Capital Partners Ltd Partnership has 1.10M shares for 4.73% of their portfolio. Tru Of Oklahoma holds 0% of its portfolio in Celgene Corporation (NASDAQ:CELG) for 16,260 shares. Headinvest Ltd Liability holds 11,297 shares or 0.3% of its portfolio. The Japan-based Daiwa Securities Gp Inc has invested 0.04% in Celgene Corporation (NASDAQ:CELG). Baupost Group Lc Ma holds 3.17% or 4.00M shares. 23,811 were accumulated by Landscape Mngmt Ltd Limited Liability Company. Buckingham Cap holds 32,980 shares. The Ontario – Canada-based Toronto Dominion Bancorp has invested 0.08% in Celgene Corporation (NASDAQ:CELG). Stock Yards Bank And Tru accumulated 14,912 shares or 0.14% of the stock. Rnc Cap Limited Liability Corporation has 3,125 shares. New York-based Neville Rodie Shaw has invested 1.02% in Celgene Corporation (NASDAQ:CELG). Legacy Private Tru holds 0.15% or 13,079 shares. Moreover, Invest Mngmt Of Virginia Limited Liability Company has 0.26% invested in Celgene Corporation (NASDAQ:CELG). Baldwin Investment Llc stated it has 0.58% in Celgene Corporation (NASDAQ:CELG). Baillie Gifford & Comm has invested 0.01% in Celgene Corporation (NASDAQ:CELG).

Celgene Corporation (NASDAQ:CELG) Ratings Coverage

Among 5 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Celgene has $103 highest and $95 lowest target. $100.20’s average target is 7.38% above currents $93.31 stock price. Celgene had 16 analyst reports since February 26, 2019 according to SRatingsIntel. As per Tuesday, March 12, the company rating was maintained by Robert W. Baird. Robert W. Baird maintained Celgene Corporation (NASDAQ:CELG) rating on Thursday, February 28. Robert W. Baird has “Buy” rating and $101 target. On Monday, June 24 the stock rating was maintained by Cantor Fitzgerald with “Hold”. Cantor Fitzgerald maintained Celgene Corporation (NASDAQ:CELG) rating on Thursday, February 28. Cantor Fitzgerald has “Buy” rating and $100 target. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Mizuho on Monday, June 24. The stock has “Buy” rating by Jefferies on Thursday, February 28. Below is a list of Celgene Corporation (NASDAQ:CELG) latest ratings and price target changes.

24/06/2019 Broker: Mizuho Rating: Buy New Target: $103 Maintain
24/06/2019 Broker: Cantor Fitzgerald Rating: Hold New Target: $100 Maintain
03/05/2019 Broker: BidaskScore Rating: Hold Upgrade
03/05/2019 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Downgrade
26/04/2019 Broker: BidaskScore Rating: Sell Downgrade
05/04/2019 Broker: Cantor Fitzgerald Old Rating: Overweight New Rating: Neutral Downgrade
01/04/2019 Broker: Bernstein Old Rating: Outperform New Rating: Market Perform Downgrade
01/04/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Downgrade
01/04/2019 Broker: Atlantic Securities Old Rating: Overweight New Rating: Neutral Downgrade
26/03/2019 Broker: Canaccord Genuity Rating: Hold Maintain

The stock increased 0.45% or $0.42 during the last trading session, reaching $93.31. About 2.19M shares traded. Celgene Corporation (NASDAQ:CELG) has risen 3.32% since August 15, 2018 and is uptrending. It has outperformed by 3.32% the S&P500.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $66.13 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 12.75 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “After-Hours Earnings Report for July 30, 2019 : AAPL, AMGN, GILD, MDLZ, CELG, PSA, AMD, ALL, EQR, OKE, EA, VRSK – Nasdaq” on July 30, 2019, also Globenewswire.com with their article: “Block & Leviton Announces $55 Million Settlement in Antitrust Case Against Celgene – GlobeNewswire” published on July 24, 2019, Nasdaq.com published: “Agios Rides High on Tibsovo Sales Amid Acute Competition – Nasdaq” on August 15, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates – Nasdaq” published on July 31, 2019 as well as Nasdaq.com‘s news article titled: “Celgene (CELG) Gains But Lags Market: What You Should Know – Nasdaq” with publication date: July 03, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.